射血分数保留的心力衰竭患者中糖尿病状态相关的临床与超声心动图特征及心血管结局:I-Preserve 试验报告
基于 I-Preserve 试验,4128 例射血分数保留的心力衰竭患者中 27% 有糖尿病史,糖尿病患者充血体征更多、生活质量更差、N 末端 B 型利钠肽原更高且预后更差。中位随访 4.1 年,糖尿病患者心血管死亡或心衰住院风险升高(调整后 HR 1.75,95%CI 1.49-2.05),全因死亡风险亦升高(调整后 HR 1.59,95%CI 1.33-1.91)。
要点
- 射血分数保留心衰合并糖尿病者充血体征更多、生活质量更差、N 末端 B 型利钠肽原更高。
- 糖尿病患者心血管死亡或心衰住院调整后 HR 1.75(95%CI 1.49-2.05)。
- 糖尿病患者全因死亡调整后 HR 1.59(95%CI 1.33-1.91)。
核心结论
- 射血分数保留的心力衰竭患者中,合并糖尿病者充血体征更多、生活质量更差、N 末端 B 型利钠肽原水平更高且预后更差。
- 合并糖尿病者还表现出更明显的结构和功能超声心动图异常。
研究设计与样本
- 基于 I-Preserve 试验(厄贝沙坦治疗射血分数保留的心力衰竭)按糖尿病史分析临床与超声心动图特征及结局。
- 采用 Cox 回归模型估计心血管结局的风险比,校正年龄、性别、利钠肽和合并症等已知预测因素。
- 745 例患者有超声心动图数据,并在补充分析中额外校正。
主要发现
- 4128 例患者中 1134 例(27%)有糖尿病。
- 与非糖尿病患者相比,糖尿病患者心肌梗死史更常见(28% 对 22%)、体重指数更高(31 对 29 kg/m2)、明尼苏达心衰生活质量评分更差(48 对 40)、N 末端 B 型利钠肽原中位数更高(403 对 320 pg/mL),以上均 P<0.01。
- 糖尿病患者左心室质量和左心房面积大于非糖尿病患者。
- 糖尿病患者多普勒 E 波速度(86 对 76 cm/s;P<0.0001)和 E/e' 比值(11.7 对 10.4;P=0.010)高于非糖尿病患者。
- 中位随访 4.1 年,糖尿病患者心血管死亡或心衰住院发生率为 34%,非糖尿病者为 22%(调整后 HR 1.75;95%CI 1.49-2.05);全因死亡分别为 28% 与 19%(调整后 HR 1.59;95%CI 1.33-1.91)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究以确定糖尿病对射血分数保留的心力衰竭结局不良影响的介导因素,以及这些因素是否可被改变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with heart failure and preserved ejection fraction, little is known about the characteristics of, and outcomes in, those with and without diabetes mellitus. METHODS: We examined clinical and echocardiographic characteristics and outcomes in the I-Preserve trial (Irbesartan in Heart Failure With Preserved Ejection Fraction) according to history of diabetes mellitus. Cox regression models were used to estimate hazard ratios for cardiovascular outcomes adjusted for known predictors, including age, sex, natriuretic peptides, and comorbidity. Echocardiographic data were available in 745 patients and were additionally adjusted for in supplementary analyses. RESULTS: Overall, 1134 of 4128 patients (27%) had diabetes mellitus. Compared with those without diabetes mellitus, they were more likely to have a history of myocardial infarction (28% versus 22%), higher body mass index (31 versus 29 kg/m2), worse Minnesota Living With Heart Failure score (48 versus 40), higher median N-terminal pro-B-type natriuretic peptide concentration (403 versus 320 pg/mL; all P<0.01), more signs of congestion, but no significant difference in left ventricular ejection fraction. Patients with diabetes mellitus had a greater left ventricular mass and left atrial area than patients without diabetes mellitus. Doppler E-wave velocity (86 versus 76 cm/s; P<0.0001) and the E/e' ratio (11.7 versus 10.4; P=0.010) were higher in patients with diabetes mellitus. Over a median follow-up of 4.1 years, cardiovascular death or heart failure hospitalization occurred in 34% of patients with diabetes mellitus versus 22% of those without diabetes mellitus (adjusted hazard ratio, 1.75; 95% confidence interval, 1.49-2.05), and 28% versus 19% of patients with and without diabetes mellitus died (adjusted hazard ratio, 1.59; confidence interval, 1.33-1.91). CONCLUSIONS: In heart failure with preserved ejection fraction, patients with diabetes mellitus have more signs of congestion, worse quality of life, higher N-terminal pro-B-type natriuretic peptide levels, and a poorer prognosis. They also display greater structural and functional echocardiographic abnormalities. Further investigation is needed to determine the mediators of the adverse impact of diabetes mellitus on outcomes in heart failure with preserved ejection fraction and whether they are modifiable. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00095238.
引用
- Kristensen SL, Mogensen UM, Jhund PS, et al. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation. 2017. PMID: 28052977. doi:10.1161/CIRCULATIONAHA.116.024593
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。